Tag: Onapgo

Over 10 million people worldwide are living with Parkinson's disease, a progressive neurological disorder. Managing symptoms has seen significant advancement with the question, **what is the new drug for Parkinson's disease?**, leading to recent FDA approvals for more advanced treatment options, including new infusion pumps and extended-release medications.

According to the Parkinson's Foundation, around one million people in the United States have Parkinson's disease. The newest FDA-approved drug for Parkinson's disease in 2025 is Onapgo (apomorphine hydrochloride), a continuous infusion therapy for managing motor fluctuations in advanced patients.

Although historically derived from morphine, the medication known as apomorphine does not contain morphine or bind to opioid receptors. It is primarily recognized as a potent dopamine agonist used to manage "off" episodes in people with advanced Parkinson's disease by mimicking dopamine's effect in the brain.

In February 2025, the U.S. Food and Drug Administration (FDA) approved Onapgo, the first infusion-based apomorphine therapy for advanced Parkinson's disease in the United States. This innovative treatment delivers a continuous infusion of medication via a wearable pump during waking hours.